PULMONX ANNOUNCES NATIONAL REIMBURSEMENT IN FRANCE FOR ZEPHYR ENDOBRONCHIAL VALVES, A REVOLUTIONARY TREATMENT OPTION FOR PATIENTS WITH SEVERE EMPHYSEMA/COPD
PULMONX ANNOUNCES NATIONAL REIMBURSEMENT IN FRANCE FOR ZEPHYR ENDOBRONCHIAL…
A NEW REPORT CONFIRMS SIGNIFICANT BENEFITS IN PATIENT REPORTED OUTCOMES AT ONE YEAR FOLLOWING THE NON-SURGICAL ZEPHYR VALVE PROCEDURE FOR COPD/EMPHYSEMA
A NEW REPORT CONFIRMS SIGNIFICANT BENEFITS IN PATIENT REPORTED OUTCOMES AT ONE…
PULMONX SECURES $66M IN FINANCING TO SUPPORT COMMERCIAL ACCELERATION OF THE ZEPHYR VALVE SYSTEM, A MINIMALLY-INVASIVE TREATMENT FOR SEVERE EMPHYSEMA
PULMONX SECURES $66M IN FINANCING TO SUPPORT COMMERCIAL ACCELERATION OF THE…
PULMONX NAMES INDUSTRY VETERAN TO BOARD OF DIRECTORS
PULMONX NAMES INDUSTRY VETERAN TO BOARD OF DIRECTORS Redwood City,…
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) ISSUES NEW GUIDELINES FOR COPD, RECOMMENDING SEVERE PATIENTS BE EVALUATED FOR BRONCHOSCOPIC LUNG VOLUME REDUCTION
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) ISSUES NEW GUIDELINES…
FDA APPROVES ZEPHYR ENDOBRONCHIAL VALVE FOR TREATING SEVERE EMPHYSEMA
FDA APPROVES ZEPHYR ENDOBRONCHIAL VALVE FOR TREATING SEVERE EMPHYSEMA First…